Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413699 · ClinicalTrials.gov registry record · Phase 3
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,488
- Enrollment target
NCT00413699: Completed Phase 3 study, sponsored by Pfizer.
NCT00413699 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 4,488 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (481% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413699, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,488 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550
Primary Outcome
Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each. Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb
Interventions
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,488 participants |
| Start Date | 2007-02-05 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 3 |
What the finished NCT00413699 record still lists
NCT00413699 is an interventional study that assigns participants to a tested intervention. Its 4,488 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (481% higher).
The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.
NCT00413699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00413699 about?
NCT00413699 is a clinical study titled "Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis". The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study...
What is the current status of trial NCT00413699?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,488 participants. The study started on 2007-02-05. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT00413699?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00413699?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00413699's enrollment target sits among peer trials
4,488 56th of 2000 higher than 1,945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI